Results 71 to 80 of about 54,679 (264)

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study

Frontiers in Oncology, 2020
Background: The development of biomarkers predictive of response to immune checkpoint inhibitor (ICI) therapies in advanced melanoma is an area of great interest in oncology.
Muhammad A. Khattak, Muhammad A. Khattak, Muhammad A. Khattak, Afaf Abed, Afaf Abed, Anna L. Reid, Ashleigh C. McEvoy, Michael Millward, Michael Millward, Melanie Ziman, Elin S. Gray   +10 more
doaj   +1 more source

Ipilimumab with or without nivolumab in PD1/PDL1 blockade refractory metastatic melanoma: a randomized phase 2 trial

Nature Medicine, 2023
In this randomized phase 2 trial, blockade of cytotoxic T-lymphocyte protein 4 (CTLA-4) with continuation of programmed death protein 1 (PD-1) blockade in patients with metastatic melanoma who had received front-line anti-PD-1 or therapy against ...
A. Vanderwalde, Shay Bellasea, K. Kendra, N. Khushalani, Katie M. Campbell, P. Scumpia, Lawrence F. Kuklinski, F. Collichio, J. Sosman, A. Ikeguchi, A. Victor, T. Truong, B. Chmielowski, D. Portnoy, Yuanbin Chen, K. Margolin, C. Bane, C. Dasanu, Douglas B. Johnson, Z. Eroglu, S. Chandra, Egmidio Medina, Cynthia R. Gonzalez, Ignacio Baselga-Carretero, Agustin Vega-Crespo, Ivan Perez Garcilazo, E. Sharon, S. Hu-Lieskovan, S. Patel, K. Grossmann, J. Moon, Michael C. Wu, A. Ribas   +32 more
semanticscholar   +1 more source

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

Ipilimumab-Induced Neutropenia in Melanoma

Journal of Investigative Medicine High Impact Case Reports, 2016
Ipilimumab is a human monoclonal IgG1 antibody against CTLA-4 that has been shown to prolong the overall survival of advanced melanoma. The most common adverse events associated with ipilimumab are immune-related.
Makiko Ban-Hoefen MD, Richard Burack MD, Lynn Sievert NP, Deepak Sahasrabudhe MD   +3 more
doaj   +1 more source

Single‐Cell Dissection of Tumor‐Infiltrating Lymphocytes Reveals Cellular Architecture Predictive of Therapeutic Efficacy in Acral Melanoma

Advanced Science, EarlyView.
Autologous tumor‐infiltrating lymphocyte (TIL) therapy shows promising efficacy in acral melanoma, yet determinants of durable response remain unclear. By integrating single‐cell transcriptomics and TCR sequencing, this study reveals that TIL products enriched for T follicular helper and intermediate exhausted T cells establish persistent clonal ...
Chao Zhang, Wanyi Xiao, Hongru Shen, Fenge Li, Ting Li, Weihong Zhang, Haotian Liu, Ziwei Gao, Hongyu Wang, Xiubao Ren, Kexin Chen, Xiangchun Li, Jilong Yang   +12 more
wiley   +1 more source

Gastrointestinal adverse events with combination of checkpoint inhibitors in advanced melanoma: a systematic review

Melanoma Management, 2018
Introduction: Immunotherapies, including checkpoint inhibitors (CIs) such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) inhibitors, are revolutionizing the treatment of advanced melanoma.
Elizabeth S Mearns, Jill A Bell, Aaron Galaznik, Stefanie M Puglielli, Allie B Cichewicz, Talia Boulanger, Ignacio Garcia-Ribas   +6 more
doaj   +1 more source

ROS Self‐Supply Nanoplatform Based on Fenton Catalyst for Chemodynamic and Immunotherapy: Reprogramming Cold Tumor Into Hot Tumor in Cancer Treatment

Advanced Science, EarlyView.
A multifunctional HA‐conjugated nanoplatform (HA‐PGMC) integrates CuO2, glucose oxidase, and mil‐100 to enable cascade catalytic ROS generation in tumor microenvironments. This self‐supplying ROS strategy induces immunogenic cell death, reprograms “cold” tumors into “hot” ones, and synergizes with PD‐L1 blockade, achieving potent chemodynamic ...
Man Lung Lee, Jack Chun Hin Chen, Wai Wing Cheng, Kwan Yee Lau, Hiu Yee Kwan, Ngar‐Yun Ellen Poon, Hung‐Wing Li   +6 more
wiley   +1 more source

An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients. [PDF]

PLoS ONE, 2018
Expression of cytotoxic T-lymphocyte antigen 4 (CTLA-4), a negative regulator of T-cell function, is increased in chronic HIV-1 infection. It was hypothesized that CTLA-4 blockade may enhance immune response to HIV-1 and result in better control of ...
Elizabeth Colston, Dennis Grasela, David Gardiner, R Pat Bucy, Blisse Vakkalagadda, Alan J Korman, Israel Lowy   +6 more
doaj   +1 more source

Prospective Randomised Phase-II Trial of Ipilimumab/Nivolumab versus Standard of Care in non-clear cell Renal Cell Cancer - Results of the SUNNIFORECAST Trial.

Annals of Oncology
BACKGROUND Non-clear cell renal cell cancers (nccRCCs) are a heterogeneous group of more than 20 different entities, but are rarely included in large, randomized trials.
L. Bergmann, L. Albiges, M. Ahrens, M. Gross-Goupil, E. Boleti, G. Gravis, A. Fléchon, M. Grimm, J. Bedke, P. Barthélémy, D. Castellano, B. Mellado, P. Iványi, S. Rottey, A. Flörcken, C. Suárez, P. Maroto, V. Grünwald, S. Oosting, J. Kopecký, S. Zschäbitz, M. Boegemann, T. Buchler, G. Niegisch, P. Goebell, T. Waddell, F. Joly, F. Priou, M. Retz, S. Siemer, U. Zimmermann, D. Deckbar, I. Burkholder, A. Hartmann, J. Haanen   +34 more
semanticscholar   +1 more source